Angola
Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Angola

2. Grant number: 17-AG0-18d-X / 17-AG0-08I-Y

3. Date of Decision Letter: 07 June 2017

4. Date of the Partnership Framework Agreement: 04 October 2013

5. Programme title: NVS, Measles-Rubella Catch-up Campaign¹

6. Vaccine type: Measles rubella

7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 doses per vial, LYOPHILISED

8. Programme duration²: 2017

9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2017</th>
<th>Total³</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US$4,554,500</td>
<td>US$4,554,500</td>
</tr>
</tbody>
</table>


11. Indicative annual amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)⁴

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Measles-Rubella vaccines doses</td>
<td>7,251,900</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$4,554,500</td>
</tr>
</tbody>
</table>

12. Procurement agency: UNICEF

13. Self-procurement: Not applicable

14. Co-financing obligations: Not applicable

15. Operational support for campaigns: Not applicable

---

¹ Exceptional catalytic support
² This is the entire duration of the Programme.
³ This is the total amount endorsed by Gavi for the entire duration of the Programme.
⁴ This is the amount that Gavi has approved.
16. Additional reporting requirements:

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Gavi Secretariat</td>
</tr>
<tr>
<td>Supplementary Immunisation Activity (SIA) technical report</td>
<td>Within 3 months of end of campaign</td>
</tr>
<tr>
<td>Post campaign coverage survey report</td>
<td>As soon as available</td>
</tr>
</tbody>
</table>

17. Financial clarifications: Not applicable

18. Other conditions:
As a condition to Gavi’s support for measles and rubella, country will be required to fully self-finance:
• 100% of the operational costs of the campaign;
• 100% of the measles rubella vaccines to be used in routine immunisation.
• 50% of the catch-up campaign doses (bundled vaccine, including AD syringes, reconstitution syringes and safety boxes)

On behalf of Gavi
Signed by
Hind Khatib-Othman
Managing Director, Country Programmes
07 June 2017